AEON Biopharma, Inc.
AEON
$0.24
$0.000.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.20% | 24.90% | 32.83% | -23.36% | -1.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.18% | 50.30% | -9.97% | -27.04% | -44.30% |
| Operating Income | -37.18% | -50.30% | 9.97% | 27.04% | 44.30% |
| Income Before Tax | 82.61% | -229.66% | -1,883.72% | 26.46% | -104.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 82.61% | -229.66% | -1,883.72% | 26.46% | -104.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 82.61% | -229.66% | -1,883.72% | 26.46% | -104.05% |
| EBIT | -37.18% | -50.30% | 9.97% | 27.04% | 44.30% |
| EBITDA | -37.35% | -50.55% | 9.96% | 27.06% | 44.39% |
| EPS Basic | 96.18% | -112.72% | -176.69% | 96.53% | -100.20% |
| Normalized Basic EPS | 95.61% | -104.06% | 82.62% | 96.59% | -121.43% |
| EPS Diluted | 96.18% | -112.72% | -176.97% | 96.53% | -100.20% |
| Normalized Diluted EPS | 95.61% | -104.06% | 82.58% | 96.59% | -121.43% |
| Average Basic Shares Outstanding | 355.61% | 919.20% | 2,225.76% | 2,018.52% | 1,954.61% |
| Average Diluted Shares Outstanding | 355.61% | 919.20% | 2,221.57% | 2,018.52% | 1,954.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |